Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma, T-Cell, Cutaneous 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 7Antilymphocyte Serum 7fludarabine phosphate 6Rituximab 6Filgrastim 6romidepsin 5Radiotherapy 5Peripheral Blood Stem Cell Transplantation 5Mycophenolic Acid 5Flow Cytometry 5Vorinostat 4Tacrolimus 4Gemcitabine 4Etoposide 4Cyclosporine 4Busulfan 4Bortezomib 4tanespimycin 3belinostat 3Whole-Body Irradiation 3Methylprednisolone 3Methotrexate 3Melphalan 3Lenalidomide 3Cord Blood Stem Cell Transplantation 3plerixafor 2nelarabine 2cobomarsen 2carfilzomib 2aldesleukin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, T-Cell, Cutaneous × sapacitabine × Clear all
NCT00476554 2021-12-22

A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma

Cyclacel Pharmaceuticals, Inc.

Phase 2 Terminated
16 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡